Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.

Abstract

DZR is a highly effective cardioprotective agent when used in patients with advanced breast cancer who continue to receive doxorubicin-based chemotherapy after a cumulative doxorubicin dose of 300 mg/m2 has been reached.

Congestive heart failure in patients treated with doxorubicin

“…every 3 weeks and were randomized to receive either DZR (500 mg/m 2 or 1000 mg/m 2 ) or placebo. 2,3 There was no maximum dose for doxorubicin, and no patients had received anthracyclines previously. The protocols for Studies 088001 and 088006 were identical.…”

“…2,3 The results of those studies indicated that DZR provided significant cardioprotection, 2 even if treatment started after a cumulative doxorubicin dose of 300 mg/m 2 had been administered. 3 The 2.2% incidence of doxorubicin-related CHF reported by Von Hoff et al 1 may not have been an accurate reflection of the true incidence of this adverse event.…”

“…2,3 The results of those studies indicated that DZR provided significant cardioprotection, 2 even if treatment started after a cumulative doxorubicin dose of 300 mg/m 2 had been administered. 3 The 2.2% incidence of doxorubicin-related CHF reported by Von Hoff et al 1 may not have been an accurate reflection of the true incidence of this adverse event. Those authors speculated that the incidence may have been underestimated due to low doses of doxorubicin administered to many of the patients, limitation of CHF reporting to investigatorobserved CHF symptoms secondary to doxorubicin, and the "usual limitations" of a retrospective study.…”

“…Those authors speculated that the incidence may have been underestimated due to low doses of doxorubicin administered to many of the patients, limitation of CHF reporting to investigatorobserved CHF symptoms secondary to doxorubicin, and the "usual limitations" of a retrospective study. 1 To determine whether the incidence of doxorubicininduced CHF is higher than that suggested by Von Hoff et al, we analyzed data from patients in the placebo arms of the 088001 and 088006 breast cancer trials 2,3 together with data from patients in the placebo arm of the 088002 lung carcinoma trial, which was a Phase III study of cyclophosphamide, doxorubicin, and vincristine (CAV), administered with or without DZR, in patients with advanced small cell lung carcinoma. 4 The primary objective of this analysis was to examine the relationship between the cumulative doxorubicin dose and the cumulative probability of developing doxorubicin-related CHF.…”

Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age

“…The addition of cardioprotective drugs such as dexrazoxane increases myelotoxicity [22] and thus probably results in limited treatment efficacy [23]. Also, the CNOP protocol with mitoxantrone substituting doxorubicin was significantly inferior to cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone (CHOP) regarding response rate and slightly inferior overall survival [24].…”